Obsidian Therapeutics

C轮

Obsidian Therapeutics, founded in 2015 by Atlas Venture, is a biotechnology company focused on the development of next-generation cell and gene therapies with pharmacologic operating systems. The company's lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy.The company is headquartered in Cambridge, MA.In November 2020, Obsidian Therapeutics and MD Anderson signed an agreement to develop novel engineered tumor infiltrating lymphocyte therapy (cytoTIL) for solid tumors. Financial terms were undisclosed.In February 2018, the company reported control of systemic IL12 levels from transduced T cells regulated in vivo using its Destabilizing Domain (DD) technology.In September 2021, Obsidian Therapeutics Inc closed a $115 million Series B financing.In December 2017, the company completed of a $49.5 million Series A financing

http://obsidiantx.com/

470305

基本信息

公司全称

Obsidian Therapeutics Inc
类型

细胞和基因疗法研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15~50人
地址

1030 Massachusetts Ave CAMBRIDGE MASSACHUSETTS 02138; US; Telephone: +17818066245;
联系电话

(781) 806-6245
邮箱

info@obsidiantx.com
成立时间

2015-01-01

投融资

2024-04-03

C轮

Wellington Management

Foresite Capital

Janus Henderson Investors

诺和诺德

Paradigm BioCapital

RTW Investments

T. Rowe Price

Woodline Partners

Atlas Venture

Blue Owl Capital

百时美施贵宝

Deep Track Capital

Logos Capital

RA Capital

Surveyor Capital

Samsara BioCapital
2021-09-09

B轮

The Column Group

Vertex Pharmaceuticals

百时美施贵宝

Amgen Ventures

Vertex Ventures HC

Atlas Venture

Soleus Capital

Samsara BioCapital

Pivotal bioVenture Partners

Logos Capital

Deep Track Capital

Cowen Healthcare Investments

Surveyor Capital

RA Capital
2017-12-06

A轮

GV

Amgen Ventures

Atlas Venture

Alexandria Venture Investments

睿智医药

Takeda Ventures

相关投融资企业

B+轮

A轮